#PTLD
I drew all the robots from The Tubbyland archives act 1. I'm really proud of how it turned out. Dipsy took like 5 hours. Ptld took atleast 10 hours in total, really proud, it's the most hardest and advanced thing I ever drew because of all the details. It turned out so good! #Teletubbies #art #noai
November 21, 2026 at 12:16 PM
We hope the follow-up study shows the same in humans as in mice. The answer to #PTLD was never going to be easy but so far #immunology looks to hold the clue. But how? Peptidoglycan, IL-23, IFNa, and more? @britsocimm.bsky.social @lochhead.bsky.social
Congratulations to Tanja on her latest paper showing that interaction with Borrelia burgdorferi leaves a lasting impact (can we call it "immuno baggage"-- the remnants of your prior relationships with bacteria?) now.tufts.edu/2026/11/19/l...
Lyme Disease Rewrites the Body’s Immune Response
A new study led by researchers at Tufts University School of Medicine suggests that infection with Borrelia burgdorferi, the bacterium that causes Lyme disease,
now.tufts.edu
November 21, 2026 at 12:44 PM
Horrendous case of acute cellular rejection. Severe tubulointerstitial inflammation and vascular rejection. Plasma cell rich which is often recalcitrant and often seen w/treatment non-adherence (be sure to r/o BK and PTLD as well). #renalpath #pathsky #nephsky
November 3, 2026 at 1:01 PM
Today is Halloween. How is it going with the teepee camping? Got cold here last night. Maybe better where you are? Sunny now in ptld. Spooky fog this morning. Gee I got a pumpkin and will carve it now. Some candy to hand out tonight.
October 31, 2026 at 9:03 PM
Hmhm chắc nhìn cũng ra mà he 😭 sau lưng b í lấy cảm hứng từ cổng Ishtar đến thành Babylon (hmhm còn mấy hình vẽ trên cổng là những thành viên còn lại của đoàn ptlđ nếu họ...)
October 30, 2026 at 2:48 PM
Tomorrow, join us for a webinar hosted by our PTLD working group:

Establishing a minimum dataset for future PTLD research

📅 22 October 2026
🕒 15:00–16:00 CEST

Agenda and registration is here https://tinyurl.com/yc6u6mre
#PTLD #TBResearch #LungHealth #GlobalHealth
October 21, 2026 at 2:00 PM
Post-TB lung disease (PTLD) affects ~50% of PTB patients. A 3-gene mHR score predicts obstructive PTLD at 6 & 12 months (P=.003, .012) but not restriction.🔬📊
A Whole-blood Transcriptional Signature Associated With Obstructive Post-tuberculosis Lung Disease
Post-tuberculosis (TB) lung disease (PTLD) affects ∼50% of persons with pulmonary TB (PTB). We recently discovered whole blood transcriptional signatures associated with PTLD. We examined whether a minimum gene signature predicts PTLD as a clinically useful biomarker.MethodsWe prospectively enrolled 301 treatment naive adults with newly diagnosed PTB (cohort A). We collected whole blood at 0 and 6-month visits, isolated RNA, and measured a modified MTB host response (HR) signature (mHR) based on expression of DUSP3, GBP5, and TMBIM6. We recorded spirometry at 6 (n = 216) and 12 months (n = 210) after treatment initiation and examined the association of the mHR score with PTLD and Mtb aerosolization. We recruited household contacts of cohort A to compare mHR score with non-PTB participants (cohort B).ResultsmHR was associated with TB (P = 4.15e−66) when compared to HHCs, treatment response (P = 1.07e−53), and characteristics including CD4 count (P = .003), bacillary load (P = 3.02e−05), lung cavities (P = 1.59e−04), and lung quadrants involved (P = 3.87e−06). The mHR score was not associated with Mtb aerosolization. In total, 105 (50%) participants had PTLD at 12 months including 61 with restriction, 26 with obstruction, and 18 with mixed obstruction and restriction. Baseline mHR was associated with obstructive PTLD at both 6 (P = .003) and 12 months (P = .012) in bivariate and multivariate analyses. The mHR score was not associated with restrictive lung disease.ConclusionsBaseline mHR was associated with obstructive PTLD at 6 and 12 months and may have applications in targeting treatment and prognostication.
academic.oup.com
October 21, 2026 at 5:00 PM
Fellow Mainers! Vote now!
I’m in line to vote at Ptld City Hall as I’m typing. Why wait? Do it today.Please join me in electing Troy!
Two weeks until Mainers vote to start building a government that works for us ✊
October 20, 2026 at 4:15 PM
Watch Nina Babel, Daan Dierickx, Sylvain Choquet, and Susan Prockop discuss latest approaches to managing posttransplant lymphoproliferative disorder (PTLD) in our EBAC-accredited webinar

https://ow.ly/gYKz50ZYP1S
October 19, 2026 at 9:00 AM
My pleasure last month to present 2 oral abstracts at the Transplantation Society biennial Congress in Sydney, from our NIAID funded PTLD MSMS study and our NIDDK funded CISTEM2 study. Got new collaborations from the audience! #TTS2026 @rwjms.bsky.social @rwjbarnabashealth.bsky.social
October 16, 2026 at 9:59 PM
The @fda.gov has accepted a resubmit BLA seeking the approval of tabelecleucel for the treatment adult and pediatric patients 2 years of age and older with EBV+ PTLD who have received at least 1 prior therapy #oncology

Read more: www.onclive.com/view/fda-acc...
October 14, 2026 at 2:15 PM
Stay ahead of the latest approaches to PTLD care with our on-demand webinar recording. Earn 1 CME credit and gain expert guidance from Nina Babel, Daan Dierickx, Sylvain Choquet, and Susan Prockop (for HCPs outside of the UK and Ireland only)
https://ow.ly/m31K50ZWmXP
October 9, 2026 at 3:50 PM
Join us for a webinar hosted by our PTLD working group:

Establishing a minimum dataset for future PTLD research

📅 22 October 2026
🕒 15:00–16:00 CEST

Agenda and registration is here https://tinyurl.com/yc6u6mre
#PTLD #TBResearch #LungHealth #GlobalHealth
October 7, 2026 at 2:00 PM
Not Lee! I was there Wednesday and still still suffering from PTLD.
October 5, 2026 at 1:34 AM
Last week's #OncFive:

✅ Pirtobrutinib OK'd in 1L CLL/SLL #lymsm #leusm
🎗️ Priority review: elinzanetant for breast cancer #bcsm
🩸 Tabelecleucel BLA resubmitted in EBV+ PTLD
🫁 Savolitinib+osimertinib NDA in MET+ NSCLC #lcsm
🫁 Zipalertinib NDA starts in NSCLC

🔗: www.onclive.com/view/the-onc...
The OncFive: Top Oncology Articles for the Week of 9/27/2026 | OncLive
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
www.onclive.com
October 5, 2026 at 3:44 PM
Title: Psilocybin shows early promise for lingering Lyme disease symptoms

Link: ift.tt/3joWJab

#psychedelics #PTLD #LymeDisease #spiritually integrated psychotherapy #mentalhealthcare
October 3, 2026 at 2:30 PM
Did you miss key updates in NSCLC, breast cancer, MDS, and PTLD? Test your knowledge with this week's OncLive news quiz #lcsm #bcsm #mpnsm #oncology

www.onclive.com/view/onclive...
OncLive Weekly News Quiz (10/2/2026): Did You Miss Crucial Lung Cancer, Breast Cancer, MDS, and PTLD Updates? | OncLive
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
www.onclive.com
October 2, 2026 at 2:01 PM
Join us for a webinar hosted by our PTLD working group:

Establishing a minimum dataset for future PTLD research

📅 22 October 2026
🕒 15:00–16:00 CEST

Agenda and registration is here https://tinyurl.com/yc6u6mre
#PTLD #TBResearch #LungHealth #GlobalHealth
September 28, 2026 at 2:01 PM
U.S. Adults 18+ With Diagnosed ME/CFS or PTLD: @polybiorf.bsky.social / Mount Sinai open-label lumbrokinase trial, with treatment sent to participants' homes & symptom questionnaires. polybio.org/projects/lum...
Lumbrokinase LongCOVID & ME/CFS clinical trial - PolyBio Research Foundation
Project Summary:A clinical trial to test if the fibrinolytic enzyme Lumbrokinase improves symptoms and mitigates blood clotting issues or platelet hyperactivation in...
polybio.org
September 23, 2026 at 10:07 PM
Breathe: Structural sequelae after TB underpin infectious PTLD: bacterial, fungal and non-TB mycobacterial. Complications are frequent yet under-diagnosed, worsening mortality and quality of life. https://bit.ly/4viER5M
September 23, 2026 at 11:35 AM
How can we improve care across the PTLD pathway? Register now for our EBAC-accredited webinar, live on Sept 24, 2026, to hear Nina Babel, Daan Dierickx, Sylvain Choquet, and Susan Prockop discuss diagnosis, risk stratification, escalation planning, and MDT care in PTLD
https://ow.ly/CNrP50ZL8tB
September 16, 2026 at 4:01 PM
It might not be th soil; it cld be tht we hav had a particularly hot summer (I am s. of Ptld). It seems counterintuitive, but most tomatoes dont like th 90's. I hav four tomato plants this year; so far hav gotten 6-7 vine-ripened tomatoes. (Siletz, Cosmonaut Volkov, Momotaro, and Italian Heirloom.)
September 13, 2026 at 8:43 PM
He's hopeful that it's possible to apply CAR T therapies that will have fewer side effects/less risk through phenotyping. He doesn't think it's relevant to all #MECFS or all #PTLD / #chronicLyme.

Nice talk
September 11, 2026 at 6:21 PM